Dulaglutide has shown similar effects, potentially preventing the atherosclerotic impacts of ox-LDL by inhibiting the suppression of KLF2 by the p53 protein in human aortic endothelial cells which is known to play a crucial role in protecting vascular endothelial cells from damage caused by ox-LDL
Compared to usual care, GLP-1RA use was associated with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions
Such gastrointestinal effects are a major reason for treatment discontinuation and are intrinsically linked to the mechanisms responsible for the weight loss efficacy of GLP-1RAs
In the days following your first semaglutide GLP-1 injection, you may not see immediate changes in appetite or weight, as the medication works gradually to regulate hunger and improve metabolic function